Pharmacokinetics and Metabolism of ARV‐393, a BCL6 PROTAC Degrader, in Dogs by UPLC–MS/MS and UPLC‐Q‐Exactive Orbitrap‐HRMS
Biomedical Chromatography · 2026-07 · 40 (7)
DOI: 10.1002/bmc.70498 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 26.05.2026. Verfasst von Qiuyan Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Xuzhou Central Hospital Affiliated Southeast University, Xuzhou, Jiangsu Province, China. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Liquid Chromatography-Mass Spectrometry. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
ARV‐393 is a novel PROTAC designed to degrade B‐cell lymphoma 6. To support its further development, it is necessary to disclose the pharmacokinetic and metabolism profiles. To achieve this goal, in this study, a simple and sensitive UPLC‐MS/MS method was developed for the quantification of ARV‐393 and a UPLC‐Q‐Exactive Orbitrap‐HRMS method was utilized to identify its metabolites in dog plasma. After acetonitrile‐mediated protein precipitation, the sample was separated on a Waters ACQUITY BEH C 18 column (50 mm × 2.1 mm, 1.7 μm). The mobile phase consisted of 2 mM of ammonium acetate and acetonitrile, each containing 0.1% formic acid, delivered at 0.4 mL/min. The analyte and internal standard were quantified using the transitions of m/z 898.2 → 398.2 and m/z 724.4 → 396.2, respectively. The method demonstrated excellent linearity over the concentration range of 1.0–1000 ng/mL ( r > 0.998). The validated method was successfully applied to a pharmacokinetic study of ARV‐393 in dogs. The results indicated that ARV‐393 exhibits low clearance and favorable bioavailability (64.7%). Four metabolites were tentatively identified by accurate mass and fragment ions. The proposed metabolic pathways include hydroxylation and hydrolysis. This work provides an overview of the pharmacokinetic and metabolism of ARV‐393, laying a foundation for further development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Xuzhou Central Hospital Affiliated Southeast University, Xuzhou, Jiangsu Province, China.
- Department of Clinical Pharmacy, Xuzhou Central Hospital Affiliated Southeast University, Xuzhou, Jiangsu Province, China.
ORCID-Profile: Huiying Zhang
Zitieren
APA
Wang, Q., Li, R., & Zhang, H. (2026). Pharmacokinetics and Metabolism of ARV‐393, a BCL6 PROTAC Degrader, in Dogs by UPLC–MS/MS and UPLC‐Q‐Exactive Orbitrap‐HRMS. Biomedical Chromatography, 40(7). https://doi.org/10.1002/bmc.70498
Vancouver
Wang Q, Li R, Zhang H. Pharmacokinetics and Metabolism of ARV‐393, a BCL6 PROTAC Degrader, in Dogs by UPLC–MS/MS and UPLC‐Q‐Exactive Orbitrap‐HRMS. Biomedical Chromatography. 2026;40(7). doi:10.1002/bmc.70498
BibTeX
@article{Wang2026,
author = {Wang, Qiuyan and Li, Rui and Zhang, Huiying},
title = {Pharmacokinetics and Metabolism of ARV‐393, a BCL6 PROTAC Degrader, in Dogs by UPLC–MS/MS and UPLC‐Q‐Exactive Orbitrap‐HRMS},
journal = {Biomedical Chromatography},
year = {2026},
volume = {40},
number = {7},
doi = {10.1002/bmc.70498}
}
EUVIMED